Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 May 2025 | Story André Damons | Photo Supplied
Dr Lisa Rothmann
Dr Lisa Rothmann, a plant disease epidemiologist from the University of the Free State (UFS), has been nominated in the TW Kambule-NSTF Award: Emerging Researcher category for this year’s NSTF-South32 Awards.

Dr Lisa Rothmann, a plant disease epidemiologist from the University of the Free State (UFS) who was nominated in the TW Kambule-NSTF Award: Emerging Researcher category for this year’s NSTF-South32 Awards, says that the nomination is a reminder that service through science matters.

“I am humbled by the nomination. For me, it reflects not just individual recognition, but also the shared effort of the team of postgraduate academics, research assistants, partners, and farmers with whom I've had the privilege to work with. It is affirming to see plant pathology and field-based research recognised in this way; it highlights the consistent (hard) work we do to make a meaningful contribution to agriculture and to serve the grain industry and farmers,” says Dr Rothmann. 

She was nominated by Grain South Africa (Grain SA), with whom she has been working closely since 2018 to contribute research that aligns with the organisation’s mission to strengthen the grain sector. They play a key role in supporting sustainable grain production and farmer development. 

Dr Rothmann, who is one of eight UFS researchers and a research team nominated for the NSTF-South32 Awards – also known as the ‘Science Oscars’ – is nominated for her contribution to interdisciplinary, team-based research to develop practical solutions for plant diseases in order to protect crops and empower communities. 

 

Motivation to keep growing

The Senior Lecturer in the Department of Plant Sciences within the Faculty of Natural and Agricultural Sciences (NAS) says that while she is proud of the work she has done, she sees this recognition as a team effort. Says Dr Rothmann: “It motivates me to keep growing as a researcher, rooted in impact and integrity. I’m not a prolific peer-reviewed publisher; my academic record includes 10 journal articles and one book chapter, but I have written around 50 popular articles – often as a solo author, in collaboration with postgraduates and peers.” 

“These pieces translate plant pathology topics such as the Sclerotinia life cycle, disease surveillance, and management into accessible information for producers and the public. To me, this nomination is a symbol that making a meaningful impact doesn't only come from journal impact factors. This nomination has reminded me that building a career in academia is a relay, not a race, and that lasting impact comes from investing in others.”

As a plant disease epidemiologist, she specialises in field pathology – an area of plant pathology that explores how disease epidemics in crops develop, spread, and can be effectively managed within agricultural systems. Their work centres on understanding and managing Sclerotinia diseases in oilseed and protein crops such as canola, soybean, and sunflower, as well as disease surveillance in key grain crops including dry bean, sorghum, and sunflower.

 

New research

After participating in the US-based National Sclerotinia Initiative in 2017, she was inspired to establish a South African Sclerotinia Research Network with the support of Grain SA, creating a platform for researcher collaboration, farmer engagement, and the development of on-farm management strategies. Over time, explains Dr Rothmann, their research has expanded to include cultivar screening, national disease surveys, fungicide registration trials, and the development of disease-assessment tools. More recently, they have embedded sociological surveys into sorghum disease work to better understand farmers’ knowledge and needs, ensuring that research remains practical and co-created with producers.

According to Dr Rothmann, they have been privileged to work in a space that supports producers and protects crops through applied plant disease management strategies. While high-value crops often attract attention due to export markets, the grain that feed the nation forms the backbone of food security. As part of their new research, Dr Rothman and the research team are currently contributing to the Sorghum Cluster Initiative's pre-breeding programme, where they have screened 160 accessions for diseases to support future cultivar development. 

They are also going to explore how both emerging and commercial farmers will adopt these new cultivars. She is actively seeking collaborators in sociology/psychology or similar fields to better understand farmers’ decision-making. They are developing a plant disease dashboard to map disease occurrences across South Africa – an effort aligned with the Plant Health (Phytosanitary) Act 35 of 2024 to help guide appropriate disease risk categorisation. In the long term, concludes Dr Rothmann, they hope to establish a diagnostic hub for central South Africa in partnership with Agricultural Research Council-Grain Crops to strengthen local disease identification and support producers in real time.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept